|Other Names||Retinoic acid receptor responder protein 1, Phorbol ester-induced gene 1 protein, PERG-1, RAR-responsive protein TIG1, Tazarotene-induced gene 1 protein, RARRES1, PEIG1, TIG1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13138b was selected from the C-term region of RARRES1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle.|
|Cellular Location||Membrane; Single-pass type III membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene was identified as a retinoid acid (RA)receptor-responsive gene. It encodes a type 1 membrane protein. Theexpression of this gene is upregulated by tazarotene as well as byretinoic acid receptors. The expression of this gene is found to bedownregulated in prostate cancer, which is caused by themethylation of its promoter and CpG island. Alternatively splicedtranscript variant encoding distinct isoforms have been observed.
Wheeler, H.E., et al. PLoS Genet. 5 (10), E1000685 (2009) :Kwok, W.K., et al. Cancer Genet. Cytogenet. 194(1):58-64(2009)Ohnishi, S., et al. Cell Prolif. 42(3):309-316(2009)Son, M.S., et al. Oncol. Res. 17 (11-12), 571-580 (2009) :Shutoh, M., et al. Cancer 104(8):1609-1619(2005)
If you have any additional inquiries please email technical services at email@example.com.